Global FeNO Leader NIOX Group plc is positioned as the global leader in FeNO testing with the NIOX VERO device, offering non-invasive asthma diagnostics and monitoring. This presents a solid upsell path to clinics and hospitals expanding respiratory care offerings and requiring reliable FeNO testing across diverse care settings.

Healthcare Partnerships Recent collaborations with AHSN Network and Vitalograph indicate a strategic openness to partner-distribution and co-marketing in respiratory diagnostics. Engage potential healthcare networks and distributor partners to accelerate adoption in clinics, primary care, and hospital outpatient services.

Expansion Opportunities With a global reach and a product used in clinics, hospitals, and primary care, there is potential to expand beyond current regions, especially into systems focusing on asthma management protocols, digital integration, and training services for FeNO testing.

Clinical Training Offerings NIOX emphasizes additional training and support for healthcare professionals. This creates a sales angle for premium training bundles, certification programs, and ongoing education services that accompany device deployment.

Adjacent Market Fit Past activity includes COPD device launches and collaborations with pharmaceutical players. There is potential to cross-sell or bundle respiratory monitoring solutions to COPD management programs and integrate FeNO testing with broader respiratory care workflows.